» Articles » PMID: 36695619

CD16 Natural Killer Cells in Bronchoalveolar Lavage Are Associated with Antibody-mediated Rejection and Chronic Lung Allograft Dysfunction

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2023 Jan 25
PMID 36695619
Authors
Affiliations
Soon will be listed here.
Abstract

Acute and chronic rejections limit the long-term survival after lung transplant. Pulmonary antibody-mediated rejection (AMR) is an incompletely understood driver of long-term outcomes characterized by donor-specific antibodies (DSAs), innate immune infiltration, and evidence of complement activation. Natural killer (NK) cells may recognize DSAs via the CD16 receptor, but this complement-independent mechanism of injury has not been explored in pulmonary AMR. CD16 NK cells were quantified in 508 prospectively collected bronchoalveolar lavage fluid samples from 195 lung transplant recipients. Associations between CD16 NK cells and human leukocyte antigen mismatches, DSAs, and AMR grade were assessed by linear models adjusted for participant characteristics and repeat measures. Cox proportional hazards models were used to assess CD16 NK cell association with chronic lung allograft dysfunction and survival. Bronchoalveolar lavage fluid CD16 NK cell frequency was associated with increasing human leukocyte antigens mismatches and increased AMR grade. Although NK frequencies were similar between DSA+ and DSA- recipients, CD16 NK cell frequencies were greater in recipients with AMR and those with concomitant allograft dysfunction. CD16 NK cells were associated with long-term graft dysfunction after AMR and decreased chronic lung allograft dysfunction-free survival. These data support the role of CD16 NK cells in pulmonary AMR.

Citing Articles

Immune dysregulation as a driver of bronchiolitis obliterans.

Deng K, Lu G Front Immunol. 2025; 15:1455009.

PMID: 39742269 PMC: 11685133. DOI: 10.3389/fimmu.2024.1455009.


Prognostic significance and gene co-expression network of CD16A and FGL2 in gliomas.

Cao Z, Liu X, Yan J Front Oncol. 2024; 14:1447113.

PMID: 39629005 PMC: 11611834. DOI: 10.3389/fonc.2024.1447113.


Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms.

Bery A, Belousova N, Hachem R, Roux A, Kreisel D Transplantation. 2024; 109(3):454-466.

PMID: 39104003 PMC: 11799353. DOI: 10.1097/TP.0000000000005162.


Innate and adaptive effector immune drivers of cytomegalovirus disease in lung transplantation: a double-edged sword.

Bharti R, Calabrese D Front Transplant. 2024; 3:1388393.

PMID: 38993763 PMC: 11235306. DOI: 10.3389/frtra.2024.1388393.


Macrophage and CD8 T cell discordance are associated with acute lung allograft dysfunction progression.

Calabrese D, Ekstrand C, Yellamilli S, Singer J, Hays S, Leard L J Heart Lung Transplant. 2024; 43(7):1074-1086.

PMID: 38367738 PMC: 11230518. DOI: 10.1016/j.healun.2024.02.007.


References
1.
Calabrese D, Chong T, Wang A, Singer J, Gottschall M, Hays S . NKG2C Natural Killer Cells in Bronchoalveolar Lavage Are Associated With Cytomegalovirus Viremia and Poor Outcomes in Lung Allograft Recipients. Transplantation. 2018; 103(3):493-501. PMC: 6389428. DOI: 10.1097/TP.0000000000002450. View

2.
Calabrese D, Florez R, Dewey K, Hui C, Torgerson D, Chong T . Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients. Clin Transplant. 2018; 32(8):e13332. PMC: 8103920. DOI: 10.1111/ctr.13332. View

3.
Gavin P, Song N, Kim S, Lipchik C, Johnson N, Bandos H . Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA Oncol. 2016; 3(3):335-341. PMC: 5344747. DOI: 10.1001/jamaoncol.2016.4884. View

4.
Parkes M, Halloran P, Hidalgo L . Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection. Transplantation. 2016; 101(4):e102-e111. PMC: 7228621. DOI: 10.1097/TP.0000000000001586. View

5.
Angaswamy N, Saini D, Ramachandran S, Nath D, Phelan D, Hachem R . Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation. Hum Immunol. 2010; 71(6):560-5. PMC: 2874120. DOI: 10.1016/j.humimm.2010.02.021. View